按照协议,Santhera制药将负责该产品的生产及供应,而曙...查看全文
产业链观察2022-01-04 17:19
药闻| 2022年1月4日,中国罕见病新药研发与商业化创新型企业曙方医药与瑞士Santhera制药宣布就罕见病新药Vamorolone达成独家授权协议,曙方医药获得在大中华区开发和商业化Vamorolone用于杜氏肌营养不良(DMD)及其他罕见病适应症的独家权益。协议总金额达1.24亿美元。根据协议,曙方医药将支付千...查看全文
chuminhua2022-01-04 15:41
#授权in# 1月4日,中国罕见病新药研发与商业化创新型企业曙方医药与瑞士Santhera制药宣布就罕见病新药Vamorolone达成独家授权协议,获得在大中华区开发和商业化Vamorolone用于杜氏肌营养不良(DMD)及其他罕见病适应症的独家权益,协议总金额达1.24亿美元。根据协议,曙方医药将支付千万美元级别的...查看全文
每日经济新闻2022-01-04 15:00
近年来,罕见病治疗及保障问题越来越受到关注,相关领域的医药创新也是动作频频。
2022年1月4日,中国罕见病新药研发与商业化创新型企业曙方医药与瑞士Santhera制药宣布就罕见病新药Vamorolone达成独家授权协议,曙方医药获得在华开发和商业化Vamorolone用于杜氏肌营养不良(DMD)及其他罕见...查看全文
医药魔方2020-12-18 20:50
12月17日,GSK宣布FDA批准Benlysta(贝利尤单抗),用于治疗正在接受标准疗法的活动性狼疮性肾炎(LN)成人患者。这是FDA批准的首款治疗LN的疗法。目前,贝利尤单抗静脉注射和皮下注射剂型在美国均已获批治疗系统性红斑狼疮(SLE)和LN。
此项批准是基于一项代号为BLISS-LN的III期临床研究积极...查看全文
$Anthera制药(ANTH)$ 8-K - Current report Filed: 2017-08-09 AccNo: 0001214659-17-004911 Size: 128 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Anthera制药(ANTH)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2017-08-09 AccNo: 0001214659-17-004902 Size: 3 MB 网页链接
$Anthera制药(ANTH)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2017-08-09 AccNo: 0001214659-17-004902 Size: 3 MB 网页链接
$Anthera制药(ANTH)$ 8-K - Current report Filed: 2017-07-14 AccNo: 0001214659-17-004453 Size: 15 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers 网页链接
$Anthera制药(ANTH)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2017-07-11 AccNo: 0001104659-17-044421 Size: 71 KB 网页链接
$Anthera制药(ANTH)$ 8-K - Current report Filed: 2017-06-19 AccNo: 0001193125-17-207227 Size: 259 KBItem 1.01: Entry into a Material Definitive AgreementItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory ...
$Anthera制药(ANTH)$ 8-K - Current report Filed: 2017-06-19 AccNo: 0001193125-17-207227 Size: 259 KBItem 1.01: Entry into a Material Definitive AgreementItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory ...
$Anthera制药(ANTH)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2017-06-19 AccNo: 0001193125-17-207223 Size: 432 KB 网页链接
$Anthera制药(ANTH)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2017-06-19 AccNo: 0001193125-17-207223 Size: 432 KB 网页链接
$Anthera制药(ANTH)$ 8-K - Current report Filed: 2017-06-19 AccNo: 0001193125-17-207227 Size: 259 KBItem 1.01: Entry into a Material Definitive AgreementItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory ...